Two Experimental Drugs Could Improve Psoriasis Treatment

WEDNESDAY, Mar 28 (HealthDay News) A new form of treatment
may be on a setting for people with assuage to critical cases of the
chronic skin condition famous as psoriasis.
Two studies, published in a Mar 29 emanate of a New England
Journal of Medicine, found that drugs that meddle with an immune
system proton called interleukin-17 (IL-17) led to significant
improvements in skin lesions for some-more than 75 percent of patients over a
12-week period.
Both studies were proviso 2 clinical trials, that researchers control to
determine a safest and many effective dose. The drugs subsequent have to be
tested in some-more people over a longer duration of time.
Although a efficiency of IL-17 inhibitors seems identical to that of
other biologic drugs for psoriasis that are already on a market, such as
Enbrel and Stelara, these drugs could offer patients some-more and possibly
safer options, pronounced Dr. Craig Leonardi, a clinical highbrow of
dermatology during Saint Louis University who w...